Whoop’s Advanced Labs health screenings will no longer require a subscription
Whoop has removed the subscription requirement for its Advanced Labs blood testing service, opening up health screenings to any user of its screenless fitness wearable rather than just paying members. The move comes as the market for screenless fitness trackers grows more competitive, with rivals such as Garmin and Google Fitbit launching similar products, suggesting Whoop is trying to retain customer interest by making its health data offerings more widely accessible.
The lab tests, conducted by Quest Diagnostics, still cost money on a pay-as-you-go basis, starting at around $150, but are no longer gated behind an additional membership fee. Advanced Labs screenings provide insights into cardiovascular, metabolic, hormonal and inflammatory health, and Whoop has also added Galleri, a multi-cancer early detection test, to the programme's offerings.
- Whoop drops subscription requirement for Advanced Labs blood testing
- Tests still cost from $150, run by Quest Diagnostics
- Multi-cancer detection test Galleri added amid rising market competition
New here? Start with this
Whoop makes screenless fitness bands that track activity and health measures, with data and features delivered through its app. Advanced Labs is a separate service that uses blood tests processed by Quest Diagnostics to give users information about areas such as heart, metabolic and hormonal health.
The tests are paid for individually, and removing the subscription requirement means Whoop device users can access them without also paying for a membership. The service sits in a growing market for wearable health tracking, where companies including Garmin and Google Fitbit offer competing products.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Removing the subscription requirement expands consumer access by allowing any user to purchase individual health screenings without a membership commitment. Users can now pay only for the specific tests they want rather than bundling unnecessary services, making health insights more affordable and flexible. This democratises health screening in a competitive market and prioritises accessibility.
The case against
This change unbundles services previously included with subscriptions and shifts them to à la carte pricing, increasing costs for regular users. Subscribers who relied on these tests as membership benefits now face additional charges, whilst Whoop collects health data from a much broader audience without providing membership value. The move represents revenue optimisation through service degradation rather than genuine consumer benefit.